Compare Bristol-Myers Squibb Co (BMY) vs Materials Select Sector SPDR Fund (XLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Materials Select Sector SPDR Fund — how do they compare? Bristol-Myers Squibb Co trades at $58.88 (market cap $116.30B), while Materials Select Sector SPDR Fund trades at $50.68. The key difference: Bristol-Myers Squibb Co pays a 4.42% dividend while Materials Select Sector SPDR Fund pays none. Which is the better fit depends on your goals.
| BMY | XLB | |
|---|---|---|
Market Cap | $116.30B | — |
Sector | Health | — |
52-Week High | $62.37 | $53.62 |
52-Week Low | $42.60 | $42.23 |
Enterprise Value | $152.24B | — |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
XLB trades at $50.58, down 0.61% with bearish technical signals from moving averages. The materials ETF faces mixed sentiment as recent sector gains appear priced in, though infrastructure trends provide underlying support. Key support sits at $50 with resistance at $51. Recent analysis suggests limited near-term upside despite sector tailwinds from manufacturing and energy security themes.
Outlook remains cautious with technical indicators favoring bearish momentum. The materials sector benefits from infrastructure spending but faces geopolitical sensitivity and valuation concerns after recent gains. Investment opportunity exists for long-term exposure to industrial materials, though current entry timing appears suboptimal given technical weakness and priced-in cyclical recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Materials Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: chemicals; metals and mining; paper and forest products; containers and packaging; and construction materials. The fund is non-diversified.
Read more on XLB →
